Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells 1,367 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,367 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $32.31, for a total value of $44,167.77. Following the transaction, the executive vice president now directly owns 48,017 shares in the company, valued at $1,551,429.27. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Swayze also recently made the following trade(s):

• On Thursday, January 16th, Eric Swayze sold 7,154 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36.
• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48.

Ionis Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ IONS traded up $0.23 during trading on Monday, hitting $32.13. 1,662,595 shares of the company traded hands, compared to its average volume of 1,661,709. The company has a 50-day moving average price of $35.07 and a 200-day moving average price of $40.00. Ionis Pharmaceuticals, Inc. has a 1 year low of $31.03 and a 1 year high of $52.34. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $5.07 billion, a P/E ratio of -13.17 and a beta of 0.35.

Analyst Ratings Changes

Several research firms have recently weighed in on IONS. Guggenheim reduced their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 15th. William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Finally, Wells Fargo & Company decreased their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Nicollet Investment Management Inc. grew its holdings in Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock worth $817,000 after buying an additional 294 shares in the last quarter. Amalgamated Bank boosted its position in Ionis Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock worth $399,000 after acquiring an additional 300 shares during the period. GAMMA Investing LLC grew its stake in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares in the last quarter. Itau Unibanco Holding S.A. increased its holdings in shares of Ionis Pharmaceuticals by 40.9% during the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after purchasing an additional 314 shares during the period. Finally, Bleakley Financial Group LLC raised its stake in shares of Ionis Pharmaceuticals by 2.1% during the third quarter. Bleakley Financial Group LLC now owns 16,678 shares of the company’s stock valued at $668,000 after purchasing an additional 338 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.